CROI 2024 HIV Podcast
Key HIV Studies From CROI 2024 Influencing Clinical Practice

Released: March 29, 2024

Expiration: March 28, 2025

Joseph J. Eron, Jr.
Joseph J. Eron, Jr., MD
Monica Gandhi
Monica Gandhi, MD, MPH

Activity

Progress
1
Course Completed

In this episode, Joseph J. Eron, Jr., MD, and Monica Gandhi, MD, MPH, discuss the key HIV studies from CROI 2024 that are influencing their clinical practice, including:

  • New data surrounding long-acting ART, including:
    • The CARES study of LA CAB + RPV in a Sub-Saharan African population using a public health approach
    • The IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIV
    • The ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ART
    • Updated data from San Francisco’s Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baseline
    • Case series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV alone
  • Data on comorbidities and coinfections, including:
    • A REPRIEVE proteomic analysis to elucidate mechanistic pathways of statin effects on plaque
    • The ACTG A5371 SLIM LIVER study of semaglutide for MASLD in people living with HIV
    • The impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San Francisco
  • Potential novel treatment options on the horizon for people living with HIV, including:
    • Phase II data on LEN + ISL dosed orally once weekly
    • Early data on other oral weekly options
    • Data on bNAbs in combination or with other ART agents